Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 123 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... February 14, 2020 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Five Questions With…Jim. April 28, 2022 Metastatic Breast Cancer: ESMO Clinical Practice Guideline May 29, 2026 Load more HOT NEWS The Benefits of Yoga During Cancer and How to Get Started Preparing for the End of the U.S. Public Health Emergency (PHE):... Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy
